PCM
COEPW

Prelude Capital Management’s Coeptis Therapeutics Warrants COEPW Stock Holding History

Prelude Capital Management’s Portfolio COEPW Stock Details COEPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,000
Closed – – 1369
2022
Q3 		$0 Hold
15,000
– – ﹤0.01% 1623
2022
Q2 		$1K Hold
15,000
– – ﹤0.01% 1753
2022
Q1 		$1K Hold
15,000
– – ﹤0.01% 1743
2021
Q4 		$5K Hold
15,000
– – ﹤0.01% 1950
2021
Q3 		$4K Hold
15,000
– – ﹤0.01% 1669
2021
Q2 		$8K Buy
+15,000
New +$7.63K ﹤0.01% 1606

Other funds holding COEPW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Prelude Capital Management's COEPW Position: Q4 2022 in Review

Prelude Capital Management sold out of Coeptis Therapeutics Warrants (COEPW) in Q4 2022, closing a stake of 15,000 shares.

Prelude Capital Management first reported a position in COEPW in Q2 2021 and held it in 6 quarters. The position peaked at $8K in Q2 2021. 21 funds tracked by Wall St. Rank hold COEPW as of Q4 2022.

  • Prelude Capital Management reported no remaining Coeptis Therapeutics Warrants position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 15,000 Coeptis Therapeutics Warrants shares in Q4 2022.
  • Prelude Capital Management first reported a position in Coeptis Therapeutics Warrants in Q2 2021 and held it in 6 quarters.
  • Prelude Capital Management's Coeptis Therapeutics Warrants position peaked at $8K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.